Figure 2.

Efficacy outcomes for ibrexafungerp 300 mg BID for 1 day from baseline to TOC (day 10), and follow-up (day 25) visits. A, Clinical cure, VSS scores ≤1, and rate of mycological eradication at TOC visit (day 10). B, VSS score of 0, VSS scores ≤1, and rate of mycological eradication at follow-up (day 25). C, Percentage of patients who required antifungal rescue medication while participating in the study. Clinical cure was defined as a complete resolution of VSS of acute vulvovaginal candidiasis at the TOC visit (day 10); the VSS scale is a standardized, predefined assessment for which each sign and symptom was given a numerical rating based on severity (absent = 0, mild = 1, moderate = 2, and severe = 3) to calculate a total composite score (range, 0–18); mycological eradication was defined as a negative fungal culture. Rescue medications used in these 2 treatment arms included fluconazole, Lotrisone (clotrimazole-betamethasone dipropionate), and terconazole. Abbreviations: BID, twice daily; TOC, test-of-cure; VSS, vulvovaginal signs and symptoms.